MedTrace Logo

Treatment of Resistant Hypertension: Cohort Study

NCT05087940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 731

Last updated 2023-02-22

No results posted yet for this study

Summary

This is a multicenter, prospective observational cohort study. It will compare effectiveness and safety of various add-on treatment options in regard to arterial blood pressure control in adult patients with treatment resistant hypertension: an aldosterone receptor blocker (e.g. spironolactone), a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker. The add-on therapy will be prescribed to the patients within the scope of their routine medical care, independently from the study investigators. The patients will be followed up for 6 months, with monthly visits and continuous home blood pressure diary kept by the patients themselves.

Conditions

  • Resistant Hypertension

Interventions

DRUG

Add-on therapy

Add-on drugs prescribed by internal medicine specialists within the routine health care and independently from the study investigators - one of the following: an aldosterone receptor blocker, a loop diuretic, a thiazide in large daily dose, an alpha 1 selective blocker or a beta 1 selective blocker

Sponsors & Collaborators

  • Medicinsko društvo za racionalnu terapiju Republike Srbije (MEDRAT)

    collaborator UNKNOWN

  • Galenika AD Beograd

    lead INDUSTRY

Principal Investigators

  • Branko Andjelkovic, MD · GALENIKA

  • Slobodan Jankovic, DSc, MD · University of Kragujevac, Faculty of Medical Sciences

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05087940 on ClinicalTrials.gov